Searched for
REVLIMID PATENT EXPIRY
Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...- Nifty 50 cos likely to see single-digit revenue and profit growth in December quarterNifty 50 companies are projected to see single-digit year-on-year growth in revenue and net profit for the December quarter. Analysts antic...
- Amish Shah turns bullish on pharma, remains cautious on ITIndian equities are poised for a constructive phase, with strategists anticipating earnings acceleration and a potential revival in foreign...
- Lower GST will re-energise agri and rural sectors: Ashi AnandAshi Anand suggests a GST cut on farm equipment could boost India's rural economy. He believes large-scale tariffs on medicines are unlikel...
- Cipla targets $1 bn US revenue in FY27Cipla aims for $1 billion in US sales by FY27, offsetting Revlimid's patent expiry with new launches, particularly in respiratory generics ...
- Cipla faces revenue and margin pressure ahead of Revlimid patent expiryCipla faces revenue and margin pressure due to the upcoming Revlimid patent expiry, leading to underperformance and analyst downgrades. Mar...
- Capacity push and new drugs critical for Aurobindo's healthA delay in drug approvals in the US market remains a concern for Aurobindo. The company stated that eight ANDAs (abbreviated new drug appli...
- Sumit Gupta remains positive on Cipla and Sun Pharma amid strong US generic market performanceSo, within the generic companies, from the US point of view, Cipla delivered a very good set of results supported by the niche launches. An...
- Dr Reddy's shares rally 4% as Nuvama upgrades rating to buyDr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the impact of Re...
- Sun Pharma Q1 preview: Weak Taro show, soft US sales to weigh on earningsConsolidated net profit is seen declining 1.4% YoY to Rs 2,033 crore. India’s largest pharmaceutical company by market capitalization is sc...
Load More
